SCHEMBL1255855

SCHEMBL1255855

O=C(Nc1nc(-c2ccco2)c(C(=O)C2CCCC2)s1)C1CC1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.71
KDM4E B2RXH2 4/20 0.71
POLB P06746 3/20 0.71
L3MBTL1 Q9Y468 3/20 0.71
LMNA P02545 3/20 0.71
MAPT P10636 3/20 0.71
MEN1 O00255 2/20 0.71
KMT2A Q03164 2/20 0.71
PKM P14618 1/20 0.71
NPC1 O15118 2/20 0.61
RAB9A P51151 2/20 0.61
USP2 O75604 1/20 0.61
HSD17B10 Q99714 1/20 0.61
ADORA2A P29274 12/20 0.55
ADORA1 P30542 12/20 0.55
ADORA2B P29275 10/20 0.55
ADORA3 P0DMS8 8/20 0.55
HPGD P15428 3/20 0.51
GSK3A P49840 1/20 0.49
GSK3B P49841 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1256301 0.98 ALDH1A1 (0.75) ALDH1A1KDM4EPOLBL3MBTL1LMNA
SCHEMBL1255858 0.91 KDM4E (0.62) ALDH1A1KDM4EPOLBL3MBTL1LMNA
SCHEMBL1256849 0.91 L3MBTL1 (0.61) ALDH1A1KDM4EPOLBL3MBTL1LMNA
SCHEMBL1256314 0.90 L3MBTL1 (0.60) ALDH1A1KDM4EPOLBL3MBTL1LMNA
SCHEMBL1256386 0.88 L3MBTL1 (0.65) ALDH1A1KDM4EPOLBL3MBTL1LMNA
SCHEMBL1255629 0.88 L3MBTL1 (0.58) ALDH1A1KDM4EPOLBL3MBTL1LMNA
SCHEMBL1256269 0.85 L3MBTL1 (0.65) ALDH1A1KDM4EPOLBL3MBTL1LMNA
SCHEMBL1257197 0.85 L3MBTL1 (0.55) ALDH1A1KDM4EPOLBL3MBTL1LMNA
SCHEMBL1256305 0.84 L3MBTL1 (0.57) ALDH1A1KDM4EPOLBL3MBTL1LMNA
SCHEMBL1254481 0.84 L3MBTL1 (0.54) ALDH1A1KDM4EPOLBL3MBTL1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1921077-B1 AGENT FOR TREATING AND/OR PREVENTING SLEEP DISORDER KYOWA HAKKO KIRIN CO LTD (JP) 2017-07-26 EP disclosed
EP-3002283-B1 THIAZOLE DERIVATIVES KYOWA HAKKO KIRIN CO LTD (JP) 2017-06-14 EP disclosed
EP-3002283-A1 THIAZOLE DERIVATIVES Kyowa Hakko Kirin Co., Ltd. (JP) 2016-04-06 EP disclosed
EP-1700856-B1 THIAZOLE DERIVATIVE KYOWA HAKKO KIRIN CO LTD (JP) 2015-11-11 EP disclosed
US-8889718-B2 Thiazole derivatives KYOWA HAKKO KIRIN CO., LTD. (JP) 2014-11-18 US disclosed
US-20130267509-A1 THIAZOLE DERIVATIVES KYOWA HAKKO KIRIN CO., LTD. (JP) 2013-10-10 US disclosed
US-8420827-B2 Thiazole derivatives KYOWA HAKKO KIRIN CO., LTD. (JP) 2013-04-16 US disclosed
US-20110105486-A1 THIAZOLE DERIVATIVES KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-05-05 US disclosed
US-7928098-B2 Therapeutic and/or preventive agents for a sleep disorder KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-04-19 US disclosed
US-7880013-B2 Thiazole derivatives KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-02-01 US disclosed
US-20100256361-A1 THIAZOLE DERIVATIVES KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-10-07 US disclosed
US-20100152162-A1 THERAPEUTIC AND/OR PREVENTIVE AGENTS FOR A SLEEP DISORDER KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-06-17 US disclosed
US-7718808-B2 Thiazole derivatives KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-05-18 US disclosed
EP-1921077-A1 AGENT FOR TREATING AND/OR PREVENTING SLEEP DISORDER KYOWA HAKKO KOGYO CO., LTD. (JP) 2008-05-14 EP disclosed
US-20070105919-A1 adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-05-10 US disclosed
EP-1700856-A1 THIAZOLE DERIVATIVE KYOWA HAKKO KOGYO CO., LTD. (JP) 2006-09-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130267509-A1 THIAZOLE DERIVATIVES THRA, CHD8, CYP2C8 ALDH1A1 1344/4885KDM4E 4495/4885POLB 4074/4885
US-20110105486-A1 THIAZOLE DERIVATIVES CHD8, CYP2C8, THRA ALDH1A1 769/4885KDM4E 4497/4885POLB 3342/4885
US-20100256361-A1 THIAZOLE DERIVATIVES ADORA2A, ADORA3, ADORA1 ALDH1A1 1290/4885KDM4E 4728/4885POLB 4509/4885
US-20070105919-A1 adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders ADORA2A, ADORA3, ADORA1 ALDH1A1 2843/4885KDM4E 4715/4885POLB 3037/4885
US-20100152162-A1 THERAPEUTIC AND/OR PREVENTIVE AGENTS FOR A SLEEP DISORDER HCRTR1, MTNR1A, HCRTR2 ALDH1A1 638/4885KDM4E 2896/4885POLB 3885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.